Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A.
PRICE/FCF RATIO
N/A
Market Cap
$2.64B
Price/FCF Ratio
18.30
TTM Avg
94.00
3Y Avg
94.62
5Y Avg
94.62
Market Cap
$6.19B
Price/FCF Ratio
83.62
TTM Avg
83.50
3Y Avg
72.16
5Y Avg
72.16
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $439.69M | 19.84 | 29.57 | 30.30 | 30.40 |
| Shoulder Innovations, Inc. (SI)vs › | $471.59M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.21B | 5.38 | 5.72 | 7.50 | 14.18 |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 18.30 | 94.00 | 94.62 | 94.62 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.68B | 25.70 | 23.41 | 21.70 | 20.29 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.19B | 83.62 | 83.50 | 72.16 | 72.16 |
| Tempus AI, Inc. (TEM)vs › | $7.69B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | 3.68 | 4.19 | 6.72 | 8.37 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.80B | 24.56 | 22.57 | 36.21 | 47.17 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute